NYON, Switzerland--(BUSINESS WIRE)--Edwards Lifesciences today announced the launch in Europe of the SAPIEN 3 transcatheter pulmonary valve implantation (TPVI) system with Alterra adaptive prestent, ...

IRVINE, Calif., Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced U.S. Food and Drug ...

The FDA approved a new version of Edwards Lifesciences’ Sapien 3 transcatheter heart valve—coupling it with a self-expanding, stent-like device that helps reshape a malfunctioning pulmonary valve.

(RTTNews) - Edwards Lifesciences (EW) said it received approval from the U.S. Food and Drug Administration for the use of the Edwards SAPIEN 3 transcatheter valve with the Alterra adaptive prestent ...

The FDA gave the greenlight to transcatheter pulmonic valve replacement with the Sapien 3 system plus an adaptive pre-stent landing zone, dubbed Alterra, for patients with congenital heart disease.

Edwards Lifesciences Corp. appears to be milking as many indications as possible from its transcatheter heart valve (THV) platform. The FDA just approved the company's Sapien XT valve for pulmonic ...

The US Food and Drug Administration (FDA) has approved use of the Edwards SAPIEN 3 transcatheter valve with the Alterra adaptive prestent (Sapien 3 with Alterra) for patients with severe pulmonary ...

Surgeons in the Heart Center at Boston Children's Hospital have partnered with Edwards Lifesciences to launch a clinical study of a new prosthetic heart valve for patients born with a congenital heart ...

Edwards Lifesciences Corporation, a global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced US Food and Drug Administration approval to expand ...

A heart valve used during percutaneous pulmonary valve implantation was safe and feasible in patients with congenital heart defects, according to a study published in EuroIntervention. Sebastien ...

Edwards Lifesciences today announced the launch in Europe of the SAPIEN 3 transcatheter pulmonary valve implantation (TPVI) system with Alterra adaptive prestent, expanding minimally invasive ...